Lipz/Lipz ED Adverse Reactions

Serious: Arterial thromboembolism, cerebral hemorrhage, cerebral thrombosis, coronary thrombosis, focal nodular hyperplasia of the liver, gall bladder disease, hepatic adenomas or benign liver tumors, hypertension, mesenteric thrombosis, MI, pulmonary embolism, ruptured cyst, thrombophlebitis and venous thrombosis with or without embolism, uterine leiomyoma.
Central nervous system: Dizziness, headache, mental depression, migraine.
Dermatologic: Melasma (may persist), rash (allergy).
Endocrine: Breast pain, tenderness, enlargement, secretion, diminution in lactation when given immediately postpartum.
Gastrointestinal: Abdominal cramps, bloating, cholestatic jaundice, nausea and vomiting (occurring in approximately 10-30% of patients during the first cycle, less common with low doses, and the majority resolve in 3 months).
Genital urinary: Amenorrhea during and after treatment; breakthrough bleeding (the majority, more than 80%, resolve in 3 months), spotting, change in menstrual flow, change in cervical erosion and secretions, invasive cervical cancer, temporary infertility after discontinuation, vaginal candidiasis.
Ophthalmic: Changes in corneal curvature (steepening), contact lens intolerance, neuro-ocular lesions (e.g., retinal thrombosis, optic neuritis).
Miscellaneous: Edema, reduced carbohydrate tolerance, weight change (increase or decrease), prevalence of cervical chlamydia trachomatis may be increased; hirsutism (rare).